Brezivaptan

From WikiMD's Medical Encyclopedia

Revision as of 21:25, 4 March 2025 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

A vasopressin receptor antagonist


Brezivaptan
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


Brezivaptan is a pharmaceutical compound that acts as a selective antagonist of the vasopressin receptor V1A. It is primarily investigated for its potential therapeutic applications in conditions where modulation of vasopressin activity is beneficial.

Pharmacology

Brezivaptan functions by inhibiting the action of vasopressin, a hormone that plays a crucial role in regulating water retention, blood pressure, and vascular resistance. By blocking the V1A receptor, Brezivaptan can potentially reduce vasoconstriction and lower blood pressure, making it a candidate for treating hypertension and other cardiovascular disorders.

Mechanism of Action

The mechanism of action of Brezivaptan involves selective antagonism of the V1A receptor, one of the subtypes of vasopressin receptors. The V1A receptor is predominantly found in vascular smooth muscle cells and the central nervous system. By blocking this receptor, Brezivaptan prevents vasopressin from exerting its vasoconstrictive effects, leading to vasodilation and a subsequent decrease in blood pressure.

Clinical Applications

Brezivaptan is being studied for its potential use in treating conditions such as congestive heart failure, where fluid overload and increased vascular resistance are common issues. Its ability to modulate vasopressin activity without affecting the V2 receptor, which is responsible for water reabsorption in the kidneys, makes it a promising candidate for managing fluid balance without causing significant diuresis.

Development and Research

Research on Brezivaptan is ongoing, with studies focusing on its efficacy, safety, and potential side effects. The development of Brezivaptan is part of a broader effort to create selective vasopressin receptor antagonists that can provide therapeutic benefits with minimal adverse effects.

Related pages

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.